First Booster of SARS-COV-2 mRNA Vaccine Is Not Associated With Alloimmunization and Subclinical Injury of Kidney Allograft
2023
Abstract
This prospective, observational study aims to evaluate vaccine safety, the dynamics of anti-HLA antibodies and donor-derived cell-free DNA (dd-cfDNA), and seroconversion rates following the first booster dose of an mRNA vaccine. The 3-mo follow-up of 108 SARS-CoV-2 naive KTRs is reported.
Anti-HLA antibodies, SARS-CoV-2 IgG S1/S2 antibodies, kidney graft function were measured at baseline (D0) and at 3 mo (M3); dd-cfDNA was analyzed in 79 KTRs.